BMY is looking to turn its business around, banking on the strong uptake of new drugs. The recent spate of positive ...

AdvanCell, an Australia-based radiopharmaceutical company, has raised $112m as investor interest in the radiopharma sector ...

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company ...

New heart health biopharmaceutical company Kardigan, which counts among its co-founders the director for Northwestern ...

From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024 ...

The recent acquisitions by pharmaceutical giants Johnson & Johnson and Bristol Myers Squibb, worth a combined $28billion, ...

(Bloomberg) -- Bristol Myers Squibb Co. said its new schizophrenia ... was a key piece of Bristol’s acquisition of Karuna. US regulators approved Cobenfy in September, becoming the first new ...

The drug comes from Bristol Myers Squibb's whopping $14 billion acquisition of biotech company Karuna Therapeutics at the end of 2023. But the drug's roots are in treating Alzheimer's.

Following a tough opening salvo from Starboard Value last fall, Pfizer is getting a chance to catch its breath in the ...

K-Bio leaders pursue U.S. factories and conferences during Lunar New Year K-Bio executives opt for international business ...